Finberg John - Associate Professor

Finberg John

Main Research Area

Neuropharmacology of Parkinson’s disease


Research projects

1. Neuroprotective and Neurogenic effects of low intensity magnetic fields on neurons:
Recently we have established that low intensity static magnetic fields have both neuroprotective and neurogenic-promoting effects in primary neuronal cultures. We have also made initial observations which show that similar fields have behavioral effects in normal, conscious rats. Since the human body is transparent to magnetic fields, these findings have important implications in development of new therapies directed against neurodegenerative and pyschiatric diseases. We are currently studying the mechanism of these effects on gene expression in rat brain and cultured neurons. This project is in collaboration with Prof Levi Schachter, Electrical Engineering, Technion.

2. Analysis of exhaled air content of volatile molecules in Parkinson’s disease:
This project is in collaboration with Professor Hossam Haick, Chemical Engineering, Technion, and Professor Jacob Vaya, Migal-Galilee Technology Center, Kiryat Shmona. We have found alterations in the spectrum of exhaled volatile molecules in Parkinsonian patients, as well as rats with depletion of dopaminergic neurons, and are developing this finding as a possible technique to detect early stage Parkinson’s disease, using a portable “electronic nose” system.

3. Studies on the mechanism of L-dopa-induced dyskinesia in the rat:
We are studying the occurrence of dopamine storage sites in medium spiny neurons of rat striatum using immunocytochemical analysis of dopamine. These dopamine storage sites are depleted of dopamine following lesion of the ascending nigro-striatal dopaminergic pathway, but could be repleted by administration of exogenous l-dopa. The function of the post-synaptic stored dopamine is being investigated in relation to L-dopa-induced dyskinesia.


Journal articles

Click here for a list of available publications in PubMed.

Items 1 – 15

1: Dayan L, Finberg JP
L-DOPA increases noradrenaline turnover in central and peripheral nervous systems.
Neuropharmacology 01/09/2003; 45: 524 – 33


2: Glezer S, Finberg JP
Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens.
Eur J Pharmacol 01/07/2003; 472: 173 – 7


3: Finberg JP, Youdim MB
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines,, reserpine reversal, serotonergic and dopaminergic behaviours.
Neuropharmacology 01/12/2002; 43: 1110 – 8


4: Youdim MB, Gross A, Finberg JP
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Br J Pharmacol 01/01/2001; 132: 500 – 6


5: Ilani T, Lamensdorf I, Finberg JP
Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Br J Pharmacol 01/08/2000; 130: 1992 – 8


6: Finberg JP, Lamensdorf I, Armoni T
Modification of dopamine release by selective inhibitors of MAO-B.
Neurobiology (Bp) 01/01/2000; 8: 137 – 42


7: Ari G, Vardi Y, Finberg JP
Nitric oxide and penile erection in streptozotocin-diabetic rats.
Clin Sci (Lond) 01/04/1999; 96: 365 – 71


8: Lamensdorf I, Porat S, Simantov R, Finberg JP
Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.
Br J Pharmacol 01/02/1999; 126: 997 – 1002


9: Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB
Pharmacology of rasagiline (N-propargyl-1R-aminoindan).
Adv Neurol 01/01/1999; 80: 495 – 9


10: Finberg JP, Takeshima T, Johnston JM, Commissiong JW
Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
Neuroreport 01/03/1998; 9: 703 – 7


11: Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS
Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.
J Neural Transm Suppl 01/01/1998; 52: 279 – 85


12: Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J
(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.
J Neural Tra,nsm Suppl 01/01/1998; 52: 301 – 5


13: Lamensdorf I, Finberg JP
Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl.
Neuropharmacology 01/10/1997; 36: 1455 – 61


14: Shachar D, Klein E, Tabak A, Finberg JP
Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain.
Eur J Pharmacol 01/08/1997; 332: 237 – 43


15: Lamensdorf I, Youdim MB, Finberg JP
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
J Neurochem 01/10/1996; 67: 1532 – 9